Differential impact of EGFR-targeted therapies on hypoxia responses: Implications for treatment sensitivity in triple-negative metastatic breast cancer

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  El Guerrab, Abderrahim ^a,b   Zegrour, Rabah ^b   Nemlin, Carine Christiane ^b   Vigier, Flavie ^b   Cayre, Anne ^a   Penault Llorca, Frederique ^a   Rossignol, Fabrice ^b   Bignon, Yves Jean ^a  

^a CENTRE JEAN PERRIN   (France)

^b Centre Biomédical de Recherche et Valorisation   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; ENHANCED GREEN FLUORESCENT PROTEIN; GEFITINIB; GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAPATINIB; ANTINEOPLASTIC AGENT; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MORTALITY; CELL HYPOXIA; CELL MIGRATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DRUG SENSITIVITY; DRUG STABILITY; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ANOXIA; BREAST TUMOR; CELL MOTION; CELL SURVIVAL; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; METABOLISM; METASTASIS; METHODOLOGY; MOLECULAR GENETICS; REPORTER GENE; TUMOR CELL LINE;

ANOXIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION, GENETIC;

EID: 80053062411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025080     Document Type: Article

References (48)

1. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
2. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374.
3. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, et al. (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134.
4. Prat A, Perou CM Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23.
5. Foulkes WD, Smith IE, Reis-Filho JS, Triple-negative breast cancer. N Engl J Med 363: 1938-1948.
6. Corkery B, Crown J, Clynes M, O'Donovan N, (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20: 862-867.
7. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
8. Mendelsohn J, (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20: 1S-13S.
9. Davidson NE, Gelmann EP, Lippman ME, Dickson RB, (1987) Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216-223.
10. Turner T, Chen P, Goodly LJ, Wells A, (1996) EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 14: 409-418.
11. Price JT, Wilson HM, Haites NE, (1996) Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer 32A: 1977-1982.
12. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, et al. (2006) Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30: 1097-1104.
13. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW, (1999) Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism. Cancer Res 59: 5475-5478.
14. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, et al. (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100: 1092-1103.
15. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, et al. (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220.
16. Le QT, Denko NC, Giaccia AJ, (2004) Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23: 293-310.
17. Semenza GL, (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35: 71-103.
18. Wenger RH, (2000) Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 203: 1253-1263.
19. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL, (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771-17778.
20. Loboda A, Jozkowicz A, Dulak J, (2010) HIF-1 and HIF-2 transcription factors-similar but not identical. Mol Cells 29: 435-442.
21. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472.
22. Tanimoto K, Makino Y, Pereira T, Poellinger L, (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309.
23. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468.
24. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML, (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858-861.
25. Semenza GL, (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578.
26. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, et al. (2002) Regulation of hypoxia-inducible factor 1 alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014.
27. Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD, et al. (2006) Akt1 activation can augment hypoxia-inducible factor-1 alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4: 471-479.
28. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, et al. (2000) Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545.
29. Italiano A, Besse B, Planchard D, Soria JC, (2007) [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]. Bull Cancer 94: F177-188.
30. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
31. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, et al. (2002) Overexpression of hypoxia-inducible factor-1 alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8: 1831-1837.
32. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
33. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396.
34. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, et al. (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369.
35. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, et al. (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66: 3197-3204.
36. Yu F, White SB, Zhao Q, Lee FS, (2001) Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res 61: 4136-4142.
37. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, et al. (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158: 905-919.
38. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, et al. (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399.
39. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083.
40. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ, (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta 1795: 162-172.
41. Kaluz S, Kaluzova M, Chrastina A, Olive PL, Pastorekova S, et al. (2002) Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res 62: 4469-4477.
42. Li X, Lu Y, Liang K, Pan T, Mendelsohn J, et al. (2008) Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther 7: 1207-1217.
43. Lu Y, Liang K, Li X, Fan Z, (2007) Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer 6: 63.
44. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z, (2005) The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24: 4433-4441.
45. Subarsky P, Hill RP, (2003) The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20: 237-250.
46. Subarsky P, Hill RP, (2008) Graded hypoxia modulates the invasive potential of HT1080 fibrosarcoma and MDA MB231 carcinoma cells. Clin Exp Metastasis 25: 253-264.
47. Fujiwara S, Nakagawa K, Harada H, Nagato S, Furukawa K, et al. (2007) Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 30: 793-802.
48. Li L, Madu CO, Lu A, Lu Y, (2010) HIF-1 alpha Promotes A Hypoxia-Independent Cell Migration. Open Biol J 3: 8-14.